Jasper Therapeutics (JSPR) Cash from Operations (2020 - 2025)

Jasper Therapeutics has reported Cash from Operations for 6 years, with the latest figure at -$21.9 million in Q4 2025.

• On a quarterly basis, Cash from Operations fell 3.78% year-over-year to -$21.9 million in Q4 2025; TTM through Dec 2025 was -$77.2 million, a 23.32% decrease from a year earlier, with the FY2025 full-year figure at -$77.2 million, down 23.32% from the prior year.
• Cash from Operations was -$21.9 million for Q4 2025 at Jasper Therapeutics, down from -$17.0 million in the prior quarter.
• The five-year high for Cash from Operations was -$5.8 million in Q2 2021, with the low at -$22.8 million in Q1 2025.
• Average Cash from Operations over 5 years is -$13.6 million, with a median of -$13.7 million recorded in 2023.
• The largest YoY upside for Cash from Operations was 42.99% in 2021 against a maximum downside of 3231.03% in 2021.
• Over 5 years, Cash from Operations stood at -$14.6 million in 2021, then increased by 13.0% to -$12.7 million in 2022, then slumped by 30.14% to -$16.5 million in 2023, then declined by 27.8% to -$21.1 million in 2024, then declined by 3.78% to -$21.9 million in 2025.
• The last three Cash from Operations figures came in at -$21.9 million (Q4 2025), -$17.0 million (Q3 2025), and -$15.5 million (Q2 2025), per Business Quant data.